Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799940 | 0.79 | ALDH1A1 (0.41) | NQO2ALDH1A1KDM4EMAPTPKM | |
| SCHEMBL24089649 | 0.79 | NQO2 (0.47) | NQO2KDM4ESMN1; SMN2CA12CA9 | |
| SCHEMBL14469417 | 0.78 | EGFR (0.73) | EGFRALDH1A1KDM4EMAPTPKM | |
| SCHEMBL799954 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTPKMHPGD | |
| SCHEMBL799605 | 0.77 | ALDH1A1 (0.44) | NQO2ALDH1A1KDM4EMAPTPKM | |
| SCHEMBL799583 | 0.76 | KMT2A (0.44) | NQO2ALDH1A1MAPTPKMHPGD | |
| SCHEMBL15691049 | 0.75 | PDE4A (0.53) | ALDH1A1KDM4EMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL28568726 | 0.75 | NPC1 (0.61) | NQO2EGFRALDH1A1KDM4EMAPT | |
| SCHEMBL13680560 | 0.75 | GSK3B (0.59) | NQO2EGFRALDH1A1KDM4EMAPT | |
| SCHEMBL24089745 | 0.74 | HDAC6 (0.40) | NQO2KDM4EHPGDCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-9428522-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2014-11-20 | — | — | US | disclosed |
| US-8822472-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7943622-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA2 | NQO2 978/4885EGFR 4253/4885ALDH1A1 1032/4885 |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CHRNA7, CHRNA5, CHRNA2 | NQO2 978/4885EGFR 4253/4885ALDH1A1 1032/4885 |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRM5 | NQO2 1001/4885EGFR 4326/4885ALDH1A1 814/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | NQO2 978/4885EGFR 4253/4885ALDH1A1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.